Novo accuses rival Eli Lilly of “deceptive” weight-loss drug ads
Nathan Bomey
Wed, July 22, 2026 at 2:55 AM GMT+5:30
2 min read
- NVO
-1.53% - LLY
-0.64%
The weight-loss drug wars reached a new level of intensity Tuesday as Novo Nordisk sued Eli Lilly, accusing its arch-rival of misleading advertising
Why it matters:Lilly and Novo are the market leaders in GLP-1 drug sales, controlling the lion’s share of the surging segment
Zoom in:Novo — the maker of Ozempic and Wegovy — alleged Tuesday that Lilly has engaged in “a nationwide pattern of deceptive advertising which confuses consumers by using outdated studies” in its ads
The Danish drug giant said Lilly’s ads compare the results from high-dosage GLP-1 treatments to lower dosages of Novo drugs that treat obesity and diabetes, with the dosage difference disclosed only in fine-print disclaimers
“People deserve evidence-based, up-to-date information they can trust when making decisions about their health,” Novo said in a statement. “Novo Nordisk has taken this step because Americans should not be denied the full picture of their treatment options.”
A Lilly spokesperson said the company — which makes Zepbound and Mounjaro — stands behind its advertising, and will “defend against this lawsuit vigorously.”
It says the study referenced in the advertisements “remains the only head-to-head, randomized clinical trial directly comparing tirzepatide and semaglutide in weight management.”
State of play:The federal lawsuit comes amid a backdrop of growing scrutiny in Washington over drug advertising
Health and Human Services Secretary Robert F. Kennedy Jr. last year announced an FDA “crackdown” on drug ads
Sen. Josh Hawley (R-Mo.) and Sen. Jeanne Shaheen (D-NH) recently introduced a bipartisan bill to kill federal subsidies for pharmaceutical ads
Sen. Bernie Sanders (I-Vt.) and Sen. Angus King (I-Maine) recently introduced a bill to ban drug ads altogether
Zoom out:The Novo suit also comes as the GLP-1 competition grows increasingly competitive with the release of oral versions of the injectable drugs, which are already proving to be popular among the public
But if Lilly investors were concerned about the conflict, it didn’t show in the stock market Tuesday. Lilly shares closed up 2.5% on the day, while Novo shares finished down 0.5% in New York
The bottom line:Novo wants a permanent injunction requiring Lilly to cease the ads on all platforms and to “conduct a corrective advertising campaign.”
AI is moving fast. Axios AI+ keeps you ahead. Sign up free atAxios.com
